Eli Lilly’s oral GLP-1 outperforms oral semaglutide in head-to-head diabetes trial
The findings add to competitive pressure on Novo Nordisk’s GLP-1 portfolio and come days after the Danish drugmaker reported that its next-generation obesity drug, CagriSema, did not meet its primary endpoint in a head-to-head study against Lilly’s tirzepatide.
The findings add to competitive pressure on Novo Nordisk’s GLP-1 portfolio and come days after the Danish drugmaker reported that its next-generation obesity drug, CagriSema, did not meet its primary endpoint in a head-to-head study against Lilly’s tirzepatide.
What's Your Reaction?
DDP Editor
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
